SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...

Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...